These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 26572909)

  • 1. Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.
    Imbs DC; Paludetto MN; Négrier S; Powell H; Lafont T; White-Koning M; Chatelut E; Thomas F
    Invest New Drugs; 2016 Feb; 34(1):41-8. PubMed ID: 26572909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.
    Li J; Brahmer J; Messersmith W; Hidalgo M; Baker SD
    Invest New Drugs; 2006 Jul; 24(4):291-7. PubMed ID: 16502356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
    Lankheet NAG; Desar IME; Mulder SF; Burger DM; Kweekel DM; van Herpen CML; van der Graaf WTA; van Erp NP
    Br J Clin Pharmacol; 2017 Oct; 83(10):2195-2204. PubMed ID: 28500677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
    Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
    Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein binding in antiretroviral therapies.
    Boffito M; Back DJ; Blaschke TF; Rowland M; Bertz RJ; Gerber JG; Miller V
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):825-35. PubMed ID: 14585213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats.
    Toyama Y; Ueyama J; Nomura H; Tsukiyama I; Saito H; Hisada T; Matsuura K; Hasegawa T
    Anticancer Res; 2014 May; 34(5):2283-9. PubMed ID: 24778032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Confidence in the Determination of Free Fraction for Highly Bound Drugs Using Bidirectional Equilibrium Dialysis.
    Chen YC; Kenny JR; Wright M; Hop CECA; Yan Z
    J Pharm Sci; 2019 Mar; 108(3):1296-1302. PubMed ID: 30326208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The binding of amsacrine to human plasma proteins.
    Paxton JW; Jurlina JL; Foote SE
    J Pharm Pharmacol; 1986 Jun; 38(6):432-8. PubMed ID: 2873219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice.
    Escudero-Ortiz V; Pérez-Ruixo JJ; Valenzuela B
    Ther Drug Monit; 2015 Apr; 37(2):172-9. PubMed ID: 25072946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of total and unbound concentrations of lopinavir in plasma using liquid chromatography-tandem mass spectrometry and ultrafiltration methods.
    Illamola SM; Labat L; Benaboud S; Tubiana R; Warszawski J; Tréluyer JM; Hirt D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Aug; 965():216-23. PubMed ID: 25049210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS.
    Paludetto MN; Puisset F; Le Louedec F; Allal B; Lafont T; Chatelut E; Arellano C
    J Pharm Biomed Anal; 2018 May; 154():373-383. PubMed ID: 29571135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total flucloxacillin plasma concentrations poorly reflect unbound concentrations in hospitalized patients with Staphylococcus aureus bacteraemia.
    Chin PKL; Drennan PG; Gardiner SJ; Zhang M; Dalton SC; Chambers ST; Begg EJ
    Br J Clin Pharmacol; 2018 Oct; 84(10):2311-2316. PubMed ID: 29908071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.
    Villarroel MC; Pratz KW; Xu L; Wright JJ; Smith BD; Rudek MA
    Invest New Drugs; 2012 Dec; 30(6):2096-102. PubMed ID: 22089297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
    Lakhani N; Sparreboom A; Venitz J; Dahut WL; Figg WD
    Anticancer Drugs; 2006 Sep; 17(8):977-83. PubMed ID: 16940808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the Serum Unbound Fraction of Tadalafil in Children with Protein-Losing Enteropathy and Its Specific Binding to Human Serum Proteins in Vitro.
    Shigetomi N; Kamiya K; Takamori T; Yoshimura N; Ozawa S; Hirono K; Ichida F; Taguchi M
    Biol Pharm Bull; 2019; 42(1):110-115. PubMed ID: 30606983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry.
    Deng Y; Wong H; Graham RA; Liu W; Shen HS; Shi Y; Wang L; Meng M; Malhi V; Ding X; Dean B
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(22):2119-26. PubMed ID: 21704573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC-MS/MS assay and ultrafiltration method.
    Arellano C; Gandia P; Lafont T; Jongejan R; Chatelut E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Oct; 907():94-100. PubMed ID: 23000741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unbound fraction of ertapenem in intensive care unit patients.
    Liebchen U; Kratzer A; Wicha SG; Kees F; Kloft C; Kees MG
    J Antimicrob Chemother; 2014 Nov; 69(11):3108-11. PubMed ID: 24962030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?
    Gandia P; Arellano C; Lafont T; Huguet F; Malard L; Chatelut E
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):531-6. PubMed ID: 23183914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of unbound drug in pharmacokinetics/pharmacodynamics and in therapy.
    Calvo R; Lukas JC; Rodriguez M; Leal N; Suarez E
    Curr Pharm Des; 2006; 12(8):977-87. PubMed ID: 16533165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.